|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Pharmacogenomics: an Assessment of Market Conditions and Competition
Academy Health finds that the nascent science of pharmacogenomics (PGx), i.e. how drugs interact with genetics, faces several formidable challenges before it can become widespread in the marketplace—particularly because our reimbursement system is badly aligned with the concept of personalized medicine.
Not only do PGx products and services stand to reduce adverse drug reactions, they have the potential to: 1) speed the approval process for drugs, reducing the cost of clinical trials (by using genetic tests to target a defined patient population); 2) reduce the length of time patients are on medication; 3) reduce the number of medications patients must take in order to find an effective therapy; and 4) reduce of the effects of disease in the body through early detection...
|home spotlight commentary research events news about contact links archives|